3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1/2
2
Phase 1
2
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia
6
Neuroblastoma
4
Lymphoma
4
Leukemia, Myeloid, Acute
4
Melanoma
3
Sarcoma
2
Rhabdomyosarcoma
2
Radiation Injuries
2
Malignant mesenchymal tumor
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Head and Neck Neoplasms
2
Congenital Abnormalities
2
Breast Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Tongue Neoplasms
1
Stomatitis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Prednisone
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
atezolizumab
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
sargramostim
×
Clear all
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled